Canada First Crohns Disease Center

Canada recently announced the nation’s first network for Crohn’s disease and ulcerative colitis patient care and research: Promoting Access and Care through Centres of Excellence (PACE). It is the most extensive Canadian collaboration for adults living with the two main manifestations of inflammatory bowel disease (IBD).

PACE will host a combination of independent and collaborative research that will take place over four years. During the first year, each center will drive their research, and in the following three years, all centers will collaborate to develop their specific strengths. Crohn’s and Colitis Canada will provide each center with $500,000.

According to a press release, Dr. Remo Panaccione, an international expert in IBD and the director of the University of Calgary’s IBD clinic since 2001, is one of five expert clinicians involved in the project. He will lead the Calgary center with Dr. Robert Fedorak, from the University of Alberta.

Canada First Crohns Disease Center

Canada First Crohns Disease Center

“The vision of PACE and the Calgary Inflammatory Bowel Disease Research Centre is to improve the quality of life of our patients with IBD —we will work to identify and target immune pathways in order to develop personalized therapies and biomarkers for disease surveillance,” said Panaccione who is also a member of the chronic disease-focused Snyder Institute for Chronic Diseases in the Cumming School of Medicine.

Calgary will be in charge of elevating the standard of care’s consistency

stablishing standard clinical practice procedures and treatments across the country. Calgary’s team will work to introduce technological alternatives for integrating best practices into healthcare.

The University of Calgary is teamed with the University of Alberta to develop standardized treatments, explicitly addressing the extended use of steroids. Steroids reduce inflammation and bring about improvement, but long-term use can also bring significant side effects. The application should be kept at a minimum.

“Our priority is reducing steroid use in Crohn’s disease and ulcerative colitis patients,” Panaccione said. “Three-quarters of patients referred to a specialist are on steroid treatment and our work will address this issue.”

Each year, Alberta sees 1,000 new IBD diagnoses. With 20,000 known cases in the province, when ranked by population, Alberta has among the highest levels of IBD burden in the world.

Read more: Canada First Crohns Disease Center

Canada First Crohns Disease Center